This site is intended for healthcare professionals only

Expert-led conference insights in malignant and non-malignant hematology
News

Radiotherapy plus cyclophosphamide–tacrolimus ‘feasible’ alloHCT regimen for AML

Published: 21st January 2021

medwireNews: Preliminary results indicate that a chemotherapy-free regimen may offer favorable outcomes for patients with high-risk acute myeloid leukemia (AML) undergoing allogeneic hematopoietic transplantation (alloHCT).

The research was presented at the virtual 62nd American Society of Hematology Annual Meeting and Exposition by Anthony Stein, from the Gehr Family Center for Leukemia Research at City of Hope in Duarte, California, USA.

The study included 18 AML patients aged 16–60 years who had achieved a first or second complete response (CR) without minimal residual disease and were undergoing alloHCT with an HLA-identical sibling donor (44.4%) or a 10/10 allele-matched unrelated donor (55.6%). 

All but one of the patients met the intermediate (50.0%) or unfavorable (44.4%) European Leukemia Network criteria for cytogenetic risk, the presenter noted.

Over the 4 days before bone marrow or peripheral blood stem cell infusion, patients were given up to 20 Gy of total marrow and lymphoid radiation targeted at the skeleton, major lymph node chains, testes, spleen, ribs, sternum, and skull, with 12 Gy aimed at the liver and brain, and lower doses to non-target regions, such as the heart and lungs.

On days 3 and 4 after transplantation, the patients were given cyclophosphamide 50 mg/kg followed by initiation of tacrolimus and G-CSF on day 5 for at least 90 days, and follow-up for a median 12.5 months.

All patients engrafted, with neutrophil and platelet recovery reported after a median 14 and 20 days, respectively.

The primary endpoint of survival free from graft-versus-host disease (GvHD) or relapse (GRFS) was achieved by 60.6% of patients at 12 months and 40.4% at 24 months, Stein reported.

Overall survival was 100% at 12 months and 85.7% after 24 months, with leukemia-free survival rates at both these time points of 83.0%.

Over the first 100 days, acute GvHD occurred at grade II–IV in 11.1% of patients and at grade III–IV in 5.6%. Chronic GvHD was reported in 29.1% at 12 months and 42.5% at 24 months, with 16.6% having experienced moderate or severe chronic GvHD by 24 months.

One patient died from progressive disease and one patient developed chronic GvHD around 1.75 years after transplantation but was improving on treatment with prednisone, tacrolimus, and ruxolitinib, Stein said.

Bearman toxicity scores showed three cases of grade 2 bladder toxicity and one case of grade 2 stomatitis but no grade 3–4 events or toxicity-related mortality.

“This chemotherapy-free conditioning regimen, together with cyclophosphamide and tacrolimus, is safe and feasible, with no non-relapse mortality,” Stein summarized.

He continued: “Almost all participants with greater than 1 years’ follow-up have discontinued immunosuppressive therapy, reducing financial burden and leading to improved quality of life.”

Noting that the “preliminary results suggest an improved GRFS rate,” he concluded that “a larger phase 2 trial is in preparation to corroborate these data.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

62nd ASH Annual Meeting and Exposition; 5–8 December 2020

Abstract 192
Probability of survival and GvHD outcomes in patients with AML

Outcome in 18 AML patients Probability at 12 months Probability at 24 months
GRFS*
60.6%
40.4%
Overall survival
100.0%
85.7%
Leukemia-free survival
83.0%
83.0%
Any chronic GvHD
29.1%
42.5%

*survival free from graft versus host disease or relapse. Abbreviations: GvHD, graft-versus-host disease; AML, acute myeloid leukemia

Source: Anthony S. Stein, Monzr M Al Malki, Dongyun Yang, et al. Total marrow and lymphoid irradiation at a dose of 2000 cGy in combination with post-transplant cyclophosphamide-based graft versus host disease prophylaxis is safe and associated with favorable GvHD-free/relapse-free survival at 1 year in patients with acute myeloid leukemia. 62nd ASH Annual Meeting and Exposition; 2020 Dec 5–8: Abstract number 192

Author: Lynda Williams

Credits  © Kateryna_Kon / stock.adobe.com

Related content.

Watch On-Demand
Interactive panel discussion
Watch On-Demand
Interactive panel discussion

Professor Jane Apperley and colleagues discuss the latest data in CML

Date & Time:
17th December 9:30-10:30am (CET)
WATCH NOW
Prof. Jane Apperley (UK) chairs an expert panel to discuss the key data and findings from the CML scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.
Disease area: CML
Watch On-Demand
Interactive panel discussion
Watch On-Demand
Interactive panel discussion

Professor John Gribben and colleagues discuss the latest data in MDS and AML

Date & Time:
16th December 3-4pm (CET)
WATCH NOW
Prof. John Gribben (UK) chairs an expert panel to discuss the key data and findings from the MDS/AML scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.
Disease area: MDS/AML
Watch On-Demand
Interactive panel discussion
Watch On-Demand
Interactive panel discussion

Professor Martin Dreyling and colleagues discuss the latest data in FL, DLBCL and MCL

Date & Time:
14th December 11am-12pm (CET)
WATCH NOW
Prof. Martin Dreyling (Germany) chairs an expert panel to discuss the key data and findings from the FL/DLBCL/MCL scientific sessions at the 62nd ASH Annual Meeting. Register now to secure your place.
Disease area: FL/DLBCL/MCL
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: GvHD

Published:
30th March 2021
Speaker: Jacopo Mariotti
Speaker Affiliation: Bone Marrow Transplantation Unit, Humanitas Research Hospital, Milan, Italy
LISTEN NOW
Dr. Jacopo Mariotti discusses his top highlights of the data and findings from the GvHD scientific sessions at the ASH 2020.
Disease area: GvHD
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: MDS/AML

Published:
22nd March 2021
Speaker: António Almeida
Speaker Affiliation: Hospital da Luz, Lisbon, Portugal
LISTEN NOW
Professor António Almeida discusses his top highlights of the data and findings from the MDS/AML scientific sessions at the ASH 2020.
Disease area: MDS/AML
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: Sickle Cell Anemia

Published:
2nd March 2021
Speaker: Giovanna Russo & Raffaella Colombatti
Speaker Affiliation: Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy (GR); Department of Women’s and Children’s Health, University of Padova, Padova, Italy (RC)
LISTEN NOW
Professor Giovanna Russo and Professor Raffaella Colombatti discuss their top highlights of the data and findings from the Sickle cell scientific sessions at the ASH 2020.
Disease area: Sickle Cell
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: Immune Thrombocytopenia

Published:
13th March 2021
Speaker: Sabine Eichinger & Johanna Gebhart
Speaker Affiliation: Department of Medicine, Medical University of Vienna, Vienna, Austria (SE, JG)
LISTEN NOW
Dr. Sabine Eichinger and Dr. Johanna Gebhart discuss their top highlights of the data and findings from the ITP scientific sessions at the ASH 2020.
Disease area: ITP
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: FL/DLBCL

Published:
9th March 2021
Speaker: Christopher Paul Fox & Wendy Osborne
Speaker Affiliation: Nottingham University Hospitals NHS Trust, Nottingham, UK (CP); Freeman Hospital and Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle, UK (WO)
LISTEN NOW
Dr. Christopher Fox and Dr. Wendy Osborne discuss their top highlights of the data and findings from the FL/DLBCL scientific sessions focusing on CAR-T cell therapies at the ASH 2020.
Disease area: FL/DLBCL
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: MPN

Published:
13th March 2021
Speaker: Massimo Breccia
Speaker Affiliation: Department of Translational and Precision Medicine, University of Rome, Rome, Italy
LISTEN NOW
Dr. Massimo Breccia discusses his top highlights of the data and findings from the MPN scientific sessions at the ASH 2020.
Disease area: MPN
Listen Now
Adis podcast
Listen Now
Adis podcast

ASH 2020 Podcast Collection: CML

Published:
15th March 2021
Speaker: Massimo Breccia
Speaker Affiliation: Department of Translational and Precision Medicine, University of Rome, Rome, Italy
LISTEN NOW
Dr. Massimo Breccia discusses his top highlights of the data and findings from the CML scientific sessions at the ASH 2020.
Disease area: CML
Read Now
News
Read Now
News

Risk factors for intracranial hemorrhage in older ITP patients identified

Published:
February 3rd 2021
Speaker: Shreeya Nanda
READ NOW
Chinese researchers have identified predictive and prognostic factors for intracranial hemorrhage in immune thrombocytopenia patients older than 60 years of age.
Disease area: ITP
Read Now
News
Read Now
News

Sutimlimab elicits ‘sustained’ responses in some chronic ITP patients

Published:
February 3rd 2021
Speaker: Shreeya Nanda
READ NOW
Extended follow-up of a phase 1b trial shows that responses to sutimlimab are maintained after more than a year of treatment in a subset of chronic immune thrombocytopenia patients with an inadequate response to multiple previous therapies.
Disease area: ITP
Watch Now
Expert interview
Watch Now
Expert interview

Gian Luca Forni - Outcomes of COVID-19 in people with hemoglobinopathies reported

Published:
21st January 2021
Speaker: Gian Luca Forni
Speaker Affiliation: Ospedale Galliera, Genoa, Italy
WATCH NOW
Gian Luca Forni shares data on the prevalence and outcomes of SARS-CoV-2 infection in Italian patients with thalassemia or sickle cell disease.
Disease area: Sickle Cell
Read Now
News
Read Now
News

Blood cell subpopulations show biomarker potential in pediatric chronic GvHD

Published:
21st January 2021
Speaker: Lucy Piper
READ NOW
Identifying certain subpopulations of T and natural killer cells could help to diagnose pediatric chronic GvHD at the onset of the disorder… (read more)
Disease area: GvHD
Watch Now
Expert interview
Watch Now
Expert interview

Rick Kapur - Understanding platelet count and bleeding outcomes in ITP

Published:
21st January 2021
Speaker: Rick Kapur
Speaker Affiliation: Sanquin Research, and Landsteiner Laboratory, Amsterdam, The Netherlands
WATCH NOW
Rick Kapur offers insights on the findings of a literature review looking at variability in platelet count and bleeding outcomes in patients with immune thrombocytopenia and the need for standardization.
Disease area: ITP
Read Now
News
Read Now
News

Rilzabrutinib achieves ‘durable response’ for heavily pretreated ITP patients

Published:
21st December 2020
Speaker: Lynda Williams
READ NOW
Early results for the oral Bruton tyrosine kinase (BTK) inhibitor rilzabrutinib support its use in patients with relapsed or refractory immune thrombocytopenia (ITP). David Kuter, from Massachusetts... (read more)
Disease area: ITP
Watch Now
Expert interview
Watch Now
Expert interview

Delphine Rea - CANDID study characterizes COVID-19 risk in CML patients

Published:
21st December 2020
Speaker: Delphine Rea
Speaker Affiliation: Hôpital Saint-Louis, Paris, France
WATCH NOW
Delphine Rea presents the International Chronic Myeloid Leukemia Foundation’s CANDID study findings showing that age is the most significant risk factor for COVID-19 mortality in CML patients.
Disease area: MPN - CML
Read Now
News
Read Now
News

Itacitinib plus CNI-based regimen shows potential for GvHD prevention after alloHCT

Published:
21st January 2021
Speaker: Lynda Williams
READ NOW
Findings from a proof-of-principle study indicate that use of the JAK1 inhibitor itacitinib alongside a calcineurin inhibitor may help prevent GvHD after transplantation… (read more)
Disease area: GvHD
Watch Now
Expert interview
Watch Now
Expert interview

Naranie Shanmuganathan - Cancer-related mutations linked to poor CML prognosis

Published:
3rd February 2021
Speaker: Naranie Shanmuganathan
Speaker Affiliation: Royal Adelaide Hospital, Australia
WATCH NOW
Naranie Shanmuganathan describes the characterization of cancer-related mutations at time of first-line treatment initiation for chronic myeloid leukemia and their relationship to patient prognosis.
Disease area: MPN-CML
Watch Now
Expert interview
Watch Now
Expert interview

Mohamad Mohty - ROCKstar: Belumosudil shows potential for refractory, advanced GvHD

Published:
16th December 2020
Speaker: Mohamad Mohty
Speaker Affiliation: Hôpital Saint-Antoine, Paris, France
WATCH NOW
Mohamad Mohty highlights the findings from the ROCKstar study showing a good response to belumosudil among heavily pretreated patients with chronic graft-versus-host disease.
Disease area: GvHD
Watch Now
Expert interview
Watch Now
Expert interview

Selim Corbacioglu - CRISPR-Cas9 gene editing shows sickle cell disease promise

Published:
16th December 2020
Speaker: Selim Corbacioglu
Speaker Affiliation: University of Regensburg, Germany
WATCH NOW
Selim Corbacioglu discusses the CLIMB SCD-121 and CLIMB THAL-111 trials demonstrating the potential of CTX001, a novel CRISPR-Cas9 gene editing therapy, for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia, respectively.
Disease area: Sickle Cell
Watch Now
Expert interview
Watch Now
Expert interview

Shehu Umar Abdullahi - SPRINT supports low-dose hydroxyurea for secondary stroke prevention in SCD

Published:
14th December 2020
Speaker: Shehu Umar Abdullahi
Speaker Affiliation: Bayero University/Aminu Kano Teaching hospital, Kano, Nigeria
WATCH NOW
Shehu Umar Abdullahi takes us through the SPRINT study establishing fixed low-dose hydroxyurea with biannual complete blood counts as an appropriate strategy in low-income settings for preventing secondary strokes in children with sickle cell disease.
Disease area: Sickle Cell
Watch Now
Expert interview
Watch Now
Expert interview

Maria Lozano - FLIGHT trial: Mycophenolate plus steroid a possible first-line option for ITP

Published:
14th December 2020
Speaker: Maria Lozano
Speaker Affiliation: University of Murcia, Spain
WATCH NOW
Maria Lozano comments on the trial showing the benefits of combining mycophenolate with corticosteroid in the first-line setting and outlines what this might mean for early intensive therapy in immune thrombocytopenia.
Disease area: ITP
Watch Now
Expert interview
Watch Now
Expert interview

Françoise Bernaudin - Study sheds light on intra- and extracranial arteriopathy in sickle cell disease

Published:
14th December 2020
Speaker: Françoise Bernaudin
Speaker Affiliation: CHIC Hospital, Créteil, France
WATCH NOW
Françoise Bernaudin reports on their research evaluating the incidence of intra- and extracranial cerebral arteriopathy, and associated risk factors, in a longitudinal, pediatric sickle cell disease cohort.
Disease area: Sickle Cell

Sharper focus. Deeper insights.